Home > Healthcare > Pharmaceuticals > Finished Drug Form > Oxycodone Drugs Market

Oxycodone Drugs Market – By Product Type (Short-acting, Long-acting Oxycodone), Dosage Form (Tablets, Capsules), Indication (Neuropathic Pain, Cancer Pain), Distribution Channel (Hospital Pharmacies, Online Pharmacies) – Global Forecast 2024 ­ 2032

  • Report ID: GMI9228
  • Published Date: Apr 2024
  • Report Format: PDF

Oxycodone Drugs Market Size

Oxycodone Drugs Market size was valued at USD 5.4 billion in 2023 and is expected to grow at a CAGR of 5.7% between 2024 and 2032, driven by factors such as the rise in incidence of chronic pain diseases such as cancer, neuropathic disease, musculoskeletal disorders, and various others.

Oxycodone Drugs Market

Also, the increase in the number of surgical procedures increases the demand for oxycodone drugs to manage postoperative pain, thereby driving market growth. For instance, according to an article published in National Library of Medicine in September 2021, it has been reported that, globally, over 310 million major surgeries are performed each year with around 40 to 50 million in U.S. and 20 million in Europe. It is estimated that up to 15% have serious postoperative morbidity, and 5–15% readmitted within 30 days. Thus, the rapid increase in the number of surgical procedures conducted globally, have increase the demand for oxycodone drugs to treat post-operative pain, thereby propelling the market growth.

Oxycodone medication is prescribed for alleviating intense pain that necessitates opioid therapy, particularly when alternative pain relief options have proven ineffective or are unsuitable. Classified as a narcotic analgesic, oxycodone operates on the central nervous system to mitigate pain. It is accessible in various forms such as capsules, tablets, and liquid, and is offered in diverse potencies.

Oxycodone Drugs Market Trends

  • The increasing prevalence of pain serves as a significant driver for the growth of the market. Chronic pain conditions, such as arthritis, back pain, neuropathic pain, and cancer-related pain, affect millions of individuals worldwide. For instance, as per the report published by U.S. Pain Foundation in 2022, 50 million Americans live with chronic pain, or pain that lasts most days or every day for three months or more. Of this group, 20 million suffer from high-impact chronic pain, or pain that interferes with basic functioning and activities of daily living, like personal hygiene and household chores.
  • Similarly, as the population ages and lifestyles change, the burden of chronic pain continues to rise. In response to this, the growing need for effective pain management drugs, such as opioid analgesics like oxycodone is used to provide relief to patients experiencing moderate to severe pain. Thus, the increase in the prevalence of chronic pain owing to musculoskeletal diseases, injuries, or post-surgical procedures is expected to boost the growth of the market.

Oxycodone Drugs Market Analysis

Oxycodone Drugs Market, By Drug Type, 2021 – 2032 (USD Billion)

Based on the drug type, the global market is classified into short-acting oxycodone and long-acting oxycodone. The long-acting oxycodone segment dominated the market with revenue of USD 3.4 billion in 2023.

  • Long-acting oxycodone formulations provide sustained pain relief over an extended period, typically ranging from 8 to 12 hours. This extended duration of action allows for better pain control, especially in patients with chronic conditions like cancer pain or neuropathic pain, where continuous analgesia is required.
  • Moreover, the convenience of less frequent dosing with long-acting oxycodone formulations promotes better adherence to the prescribed pain management regimen. Patients are more likely to adhere to treatment plans when they require fewer doses per day, leading to more effective pain control and improved clinical outcomes.
  • Such  benefits associated with long-acting oxycodone formulation will augment the market growth.


Oxycodone Drugs Market, By Dosage Form (2023)

Based on the dosage form, the global oxycodone drugs market is classified into tablets, capsules, and injections. The tablets segment dominated the market with market share of 46.3% in 2023.

  • Several patients prefer tablet dosage form, rather than injection or parenteral owing to various advantages such as accurate dosage, ease of administration, portability, and longer shelf life.
  • Moreover, the easy availability of various over-the-counter drugs such as immediate-release and extended-release oxycodone formulations is the major factor that contribute to the growth of the market. This variety allows healthcare providers to select the most appropriate formulation based on the patient's pain intensity, duration of action required, and individualized treatment goals.

Based on the indication, the global oxycodone drugs market is classified into neuropathic pain, musculoskeletal pain, cancer pain, post-operative pain, and other indications. The neuropathic pain segment dominated the market in 2023 and is expected to reach USD 3.2 billion by end of 2032.

  • The rise in prevalence of neuropathic pain globally due to various factors such as aging populations, increased survival rates of conditions that cause nerve damage (diabetes, cancer), and improved recognition and diagnosis of neuropathic pain conditions is one of the major factors that propel the growth of the market. As the incidence of neuropathic pain grows, so does the demand for effective pain management medications like oxycodone increases.
  • Moreover, oxycodone formulations approved for the treatment of moderate to severe pain, including neuropathic pain, are available in many countries. Regulatory approval ensures that oxycodone products meet quality standards and safety requirements, making them readily accessible for patients with neuropathic pain.

Based on distribution channel, the oxycodone drugs market is classified into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Hospital pharmacies segment is expected to exhibit 5.9% CAGR between 2024 - 2032.

  • The increase in the number of surgical procedures being conducted in hospitals and availability of patients for various medical conditions, surgeries, and procedures is the major factor that contribute to the demand for oxycodone-based medications within hospital settings.
  • Moreover, hospitals provide comprehensive cancer care services, including chemotherapy, radiotherapy, and pain management for cancer patients. Oxycodone is commonly used to manage cancer-related pain, contributing to its utilization within hospital pharmacies.


North America Oxycodone Drugs Market, 2021 – 2032 (USD Billion)

In 2023, North America secured a substantial market share of 42.7% in the global oxycodone drugs market and is expected to dominate throughout the forecast period. Further, the market in U.S. is expected to exhibit 5.9% CAGR between 2024 - 2032.

  • North America witnesses a significant number of surgical procedures performed annually, both elective and non-elective. Therefore, widespread usage of oxycodone to manage postoperative pain, driving demand for the drug in the region.
  • Moreover, the increase in incidence of cancer, and increase in trend of physician prescribing oxycodone to manage cancer-related pain, particularly in advanced stages of the disease are the major factors that contributes to the increase in demand for oxycodone in the U.S. market.
  • Further, the rise in the demand for opioid containing drugs to relive pain, and the higher rates of opioid prescribing in U.S. compared to other countries are the major factors that boosts the market growth.

Germany to experience the highest growth rate in the market, outstripping other countries in Europe region.

  • The increase in public awareness and education pertaining to pain management and the role of opioids like oxycodone may impact prescribing practices and patient attitudes towards opioid therapy in Germany. Thus, the increased awareness about the benefits and risks of oxycodone can drive its utilization in the market.
  • Moreover, high prevalence of chronic pain conditions, including back pain, arthritis, and neuropathic pain, and increase in patient awareness about pain management options and a growing patient demand for effective pain relief drive the utilization of oxycodone in country, thereby supplementing the growth of the market.

The India oxycodone drugs market is expected to grow with a significant CAGR during the forecast period.

  • The rise in the prevalence of chronic disease and rapid increase in geriatric population are the major factors that drive the demand for effective pain management medications like oxycodone, that will boost the market growth.
  • Moreover, India is experiencing a transition in disease patterns, with a growing burden of non-communicable diseases (NCDs) such as diabetes, cardiovascular diseases, and cancer. These conditions often lead to chronic pain, driving the demand for oxycodone and other opioid analgesics.
  • Also, pharmaceutical companies invest in marketing and educational initiatives aimed at healthcare providers to raise awareness about oxycodone and its appropriate use in pain management. These initiatives can influence prescribing practices and contribute to market growth.

Oxycodone Drugs Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical companies that involved in the manufacturing of opioid containing pain management drugs vying for market share. Key players are engaging in strategic initiatives such as collaboration, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for oxycodone drugs.

Oxycodone Drugs Market Companies

Prominent players operating in the oxycodone drugs industry are as mentioned below:

  • Alvogen
  • Ani Pharmaceuticals, Inc.
  • Daiichi Sankyo Company Ltd.
  • Endo Pharmaceuticals
  • Mallinckrodt Pharmaceuticals
  • Mylan N.V.
  • Protega Pharmaceuticals LLC
  • Purdue Pharma LP
  • Quagen Pharma
  • Teva Pharmaceuticals, Inc.

Oxycodone Drugs Industry News:

  • In July 2022, Protega Pharmaceuticals LLC announced the commercial launch of RoxyBond (oxycodone) immediate-release (IR) tablets in the U.S. market. RoxyBond was approved by the U.S. Food and Drug Administration (FDA) as an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. This strategy enabled company to outreach to untapped economies.
  • In September 2019, Daiichi Sankyo Company Limited launched a new generic formulation of oxycodone hydrochloride hydrate extended-release tablets for sustained cancer pain treatment in Japan. This strategy enabled company to add value to its existing portfolio.

The oxycodone drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

  • Short-acting oxycodone
  • Long-acting oxycodone

Market, By Dosage Form

  • Tablets
  • Capsules
  • Injections

Market, By Indication

  • Neuropathic pain
  • Musculoskeletal pain
  • Cancer pain
  • Post-operative pain
  • Other indications

Market, By Distribution Channel

  • Hospital pharmacies
  • Drug stores & retail pharmacies
  • Online pharmacies

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Netherlands
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • South Africa
    • Saudia Arabia
    • UAE
    • Rest of Middle East and Africa


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Oxycodone drugs industry size was USD 5.4 billion in 2023 and is projected to showcase 5.7% CAGR from 2024 to 2032, owing to the rise in incidence of chronic pain diseases like cancer, neuropathic disease, and musculoskeletal disorders.

The long-acting oxycodone segment in the market reached USD 3.4 billion in 2023 and is estimated to grow at substantial CAGR between 2024 and 2032, due to their convenience of less frequent dosing.

North America oxycodone drugs industry accumulated 42.7% revenue share in 2023 and is predicted to grow at notable rate between 2024 and 2032, owing to the increase in incidence of cancer and the rising trend of drug prescription to manage cancer-related pain.

Alvogen, Ani Pharmaceuticals, Inc., Daiichi Sankyo Company Ltd., Endo Pharmaceuticals, Mallinckrodt Pharmaceuticals, Mylan N.V., Protega Pharmaceuticals LLC, Purdue Pharma LP, Quagen Pharma, and Teva Pharmaceuticals, Inc.

Oxycodone Drugs Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 268
  • Countries covered: 22
  • Pages: 162
 Download Free Sample